...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Haematology >A fibrinogen concentrate Haemocomplettan? (Riastap?) or a Factor XIII concentrate Fibrogammin? combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor
【24h】

A fibrinogen concentrate Haemocomplettan? (Riastap?) or a Factor XIII concentrate Fibrogammin? combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor

机译：纤维蛋白原浓缩品（Riastap？）或XIII因子浓缩的丝柏精？与小剂量氨甲环酸合用可将血纤蛋白不稳定性逆转为凝血酶或FXa抑制剂诱导的血纤蛋白溶解

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To assess whether Haemocomplettan? (fibrinogen concentrate) or Fibrogammin? (Factor XIII concentrate) can be used to manage bleeding complications of antithrombotic treatment, we examined a normal plasma pool spiked with AR-H067637 (thrombin inhibitor) or rivaroxaban (activated factor X-inhibitor), to which one of the concentrates was added. Fibrin network permeability (Ks), images of Scanning Electron Microscopy (SEM) and Clot Lysis Time (CLT) were examined. Both inhibitors increased the Ks levels, which could be fully or partly reversed by Haemocomplettan? or Fibrogammin? respectively. However, these modified clots with tightened network remained non-resistant to fibrinolysis, shown as unaffected CLT. Tranexamic acid at a very low concentration (0??4 mg/ml) aided the two concentrates to stabilize the clots, where the prolongation of CLT was more pronounced for a lower dose than a higher dose of Haemocomplettan? while Fibrogammin? brought the greatest delay to CLT out of all additions. These observations were partly supported by SEM images, displaying alterations of fibrin fibre arrangement known to influence fibirinolysis. The in vitro data suggest that Haemocomplettan? or Fibrogammin? given in combination with a mini dose of tranexamic acid may slow down the natural clearance of fibrin clot by plasmin and thus prevent patients from haemorrhagic complications during antithrombotic therapy. ? 2013 Blackwell Publishing Ltd.
机译：评估是否有血红素完全？ （浓缩纤维蛋白原）或Fibrogammin？ （因子XIII浓缩物）可用于处理抗血栓形成治疗的出血并发症，我们检查了掺有一种浓缩物的正常血浆池，其中掺入了AR-H067637（凝血酶抑制剂）或利伐沙班（活化因子X抑制剂）。检查了血纤蛋白网络的渗透性（Ks），扫描电子显微镜（SEM）和凝块裂解时间（CLT）的图像。两种抑制剂均可提高Ks水平，而血红素完全可以逆转Ks水平吗？还是fibrogammin？分别。但是，这些修饰的血凝块具有紧绷的网状结构，对纤维蛋白溶解仍然没有抵抗力，表现为未受影响的CLT。极低浓度的氨甲环酸（0〜4 mg / ml）有助于两种浓缩物稳定血凝块，在这种情况下，较低剂量的CLT延长比较高剂量的Heemocomplettan？而Fibrogammin？在所有添加中给CLT带来了最大的延迟。这些观察结果部分得到SEM图像的支持，显示出已知会影响纤维蛋白溶解的纤维蛋白纤维排列的变化。体外数据提示血红素完全？还是fibrogammin？结合小剂量氨甲环酸一起使用可能会减慢纤溶酶对血纤蛋白凝块的自然清除，从而防止患者在抗栓治疗期间出血性并发症。 ？ 2013布莱克威尔出版有限公司

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号